Publication details
U jakého pacienta s CLL indikovat terapii novými léky?
| Title in English | In which CLL patient should therapy with new drugs be indicated? |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| web | https://www.farmakoterapie.cz/c7494/u-jakeho-pacienta-s-cll-indikovat-terapii-novymi-leky |
| Keywords | chronic lymphocytic leukaemia; ibrutinib; acalabrutinib; venetoclax; choice of treatment |
| Description | In recent decades, several new drugs have been approved, which have brought significant improvements in treatment outcomes. Treatment with these new agents should optimally be offered to all patients with CLL. Factors such as line of treatment, patient age and comorbidities, prognostic and predictive factors, adverse effects of therapy, and patient preferences should be considered when deciding on the choice of a particular molecule. The goal is to individually choose the drug that will be most suitable for the given patient in terms of effectiveness and safety. |